retatrutide mechanism gip glp-1 glucagon triple agonist Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols Retatrutide is a triple-agonist drug
Pay in 4 interest-free payments of $6.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26















![Tirzepatide vs. Semaglutide: Which GLP-1 Better Preserves Muscle? [SURMOUNT-5 Data]](https://www.clinicalnutritioncenter.com/wp-content/uploads/2026/04/research-image-2026-04-10-1024x559.jpg)






